Partner Headlines - ALKS

  1. Alkermes down after drug fails

    IBD
  2. Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes ...

    Benzinga
  3. Alkermes Hits Two-Year Low On Depression Drug Failure

    IBD
  4. Mid-Day Market Update: US Stocks Turn Higher; Plexus Shares Gain ...

    Benzinga
  5. Mid-Morning Market Update: Markets Drop; Verizon Profit Tops ...

    Benzinga
  6. 10 Stocks Moving In Thursday's Pre-Market Session

    Benzinga
  7. AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week ...

    GuruFocus
  8. Alkermes Reports Achievement of Milestones for CNS Medicines ...

    Benzinga
  9. U.S.-Traded Eurozone Stocks React Mildly To ECB Vote

    IBD
  10. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  11. Non-Opioid Therapeutics And Significant Pain Treatments Make ...

    Benzinga
  12. Benzinga's Volume Movers

    Benzinga
  13. Morning Market Gainers

    Benzinga
  14. Underappreciated Leader Skips Over Equal-Weight In Double Upgrade

    Benzinga
  15. Benzinga's Top #PreMarket Gainers

    Benzinga
  16. Benzinga's M&A Chatter for Tuesday June 16, 2015

    Benzinga
  17. US Stock Futures Decline Ahead Of Housing Starts Report

    Benzinga
  18. Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming ...

    Benzinga
  19. Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil ...

    Benzinga
  20. US Stock Futures Edge Lower; GDP Report In Focus

    Benzinga
  21. Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting ...

    Benzinga
  22. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  23. Benzinga's Top Initiations

    Benzinga
  24. Barclays Initiates Alkermes With Overweight

    Benzinga
  25. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  26. Stocks Mostly Higher: Time Warner Clears Buy Point

    IBD
  27. Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

    Benzinga
  28. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  29. Alkermes pops to 15-year high

    IBD
  30. Alkermes Hits High On Schizophrenia Drug Results

    IBD
  31. Morning Market Gainers

    Benzinga
  32. Benzinga's Top #PreMarket Gainers

    Benzinga
  33. Benzinga's Volume Movers

    Benzinga
  34. 3 Biotech ETFs Rally On Merger News

    Benzinga
  35. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga
  36. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  37. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  38. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  39. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  40. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  41. Alkermes' drug passes trial

    IBD
  42. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  43. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  44. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  45. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  46. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  47. Benzinga's Volume Movers

    Benzinga
  48. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  49. Morning Market Movers

    Benzinga
  50. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  51. Benzinga's Top Initiations

    Benzinga
  52. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  53. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  54. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  55. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  56. Stocks End Short Week With Big Losses

    IBD
  57. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  58. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  59. Ireland Home To Several Fast Growing Health Care Names

    IBD
  60. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  61. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  62. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  63. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  64. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  65. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  66. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  67. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  68. Alkermes

    IBD
  69. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  70. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  71. Alkermes

    IBD
  72. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  73. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  74. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  75. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  76. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  77. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  78. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  79. Stocks Pare Early Losses, End With Modest Declines

    IBD
  80. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  81. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  82. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  83. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  84. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  85. Dow Leads Market Higher As Volume Swells

    IBD
  86. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  87. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  88. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  89. Stocks Tumble On Disappointing Earnings Reports

    IBD
  90. Why Cisco, Google And Apple All Became Big Winners

    IBD
  91. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  92. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  93. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  94. Alkermes Writes New Prescription For Growth

    IBD
  95. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  96. Health Care Sector Wrap

    FoxBusiness
  97. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  98. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  99. Elan

    IBD
  100. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
Trading Center